UPDATE | March 24, 2026
Accelerating ADC analytical method development through platform innovation
Accelerating ADC development is not just about moving faster. It is about enabling informed, confident decision-making at every stage.
Our latest whitepaper, authored by Jaeook Kim, Associate Director of the ADC Analytical Development Group at Samsung Biologics, explores how platform-driven analytical strategies can support more efficient, reliable development.
Key highlights:
✅ Cross-modality analytical framework that integrates antibody and ADC analysis
✅ High-quality data generation, proactive risk management, and support progress toward IND and beyond
✅ A balanced approach combining platform methods, structured feasibility assessments, and targeted customization to improve readiness and predictability
Read on to see how Samsung Biologics’ differentiated approach can help create a more seamless path from development to manufacturing.
Accelerating ADC development is not just about moving faster. It is about enabling informed, confident decision-making at every stage.
Our latest whitepaper, authored by Jaeook Kim, Associate Director of the ADC Analytical Development Group at Samsung Biologics, explores how platform-driven analytical strategies can support more efficient, reliable development.
Key highlights:
✅ Cross-modality analytical framework that integrates antibody and ADC analysis
✅ High-quality data generation, proactive risk management, and support progress toward IND and beyond
✅ A balanced approach combining platform methods, structured feasibility assessments, and targeted customization to improve readiness and predictability
Read on to see how Samsung Biologics’ differentiated approach can help create a more seamless path from development to manufacturing.
Related Content